Italian biotech Cellply raises €8.1M to speed up cell therapy quality control
What's the deal? Cellply, an Italian biotech startup focused on quality control for advanced cell therapies, has raised €8.1M in a funding round led by ENEA Tech. The company develops technology to help manufacturers of cell and gene therapies assess product quality more efficiently.
Why now? The cell and gene therapy market is expanding rapidly, with dozens of new treatments moving through clinical trials and toward commercialisation. As production scales up, the need for faster, more reliable quality control tools becomes critical — a bottleneck Cellply aims to solve.
The signal: The investment reflects growing European ambition in the biotech infrastructure layer — not just developing therapies, but building the tools and platforms that make them viable at scale. ENEA Tech, a Italian government-backed fund focused on technology transfer, leading the round signals public-sector confidence in deep-tech biotech plays that support the broader advanced therapy ecosystem.
Read more: innlifes.com
